September 24, 2004

UBS Global Life Sciences Conference to Webcast Sangamo Presentation

RICHMOND, Calif., Sept. 24 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that its presentation at the UBS Global Life Sciences Conference will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under "Company Overview".

Edward Lanphier, the company's president and CEO, will deliver the presentation at 1:30 p.m. EDT on Thursday, September 30, 2004 from the Grand Hyatt Hotel in New York City.

The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The company's most advanced therapeutic development program, currently in a Phase I clinical trial, involves the use of transcription factors for the treatment of peripheral artery disease. Other therapeutic development programs are focused on diabetic neuropathy, ischemic heart disease, congestive heart failure, cancer, neuropathic pain, and infectious and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP-Nucleases (ZFNs) for therapeutic gene modification as a treatment and possible cure for a variety of monogenic diseases such as sickle cell anemia and for infectious diseases such as HIV. For more information about Sangamo, visit the company's web site at www.sangamo.com or www.expressinglife.com

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and applications of Sangamo's ZFP TF technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.

CONTACT: Elizabeth Wolffe, Ph.D, of Sangamo BioSciences, Inc.,
+1-510-970-6000, ext. 271,
or ewolffe@sangamo.com or media,
Kathy Jones-Nugent,
or investors, John Nugent,
+1-212-213-0006,
both of Burns McClellan, Inc.,
for Sangamo BioSciences, Inc.
Web site: http://www.sangamo.com


Close window | Back to top





Copyright 2014 Sangamo BioSciences, Inc.